Disease relevance of SRBD1

• SRBD is an independent risk factor for systemic hypertension with an increased likelihood in subjects </= 50 yr of age [1].
• Referred patients with suspicion of sleep-related breathing disorders (SRBD) were included in the study if, after a first selection night, their central apnea index (CAI) was > 5 or their apnea-hypopnea index (AHI) > 10 and their obstructive apnea index (OAI) < 5 [2].
• There were no significant differences in SRBD according to the stroke subtype except for the central apnea index (CAI) [3].
• Positive airway pressure (PAP) devices are used to treat patients with sleep related breathing disorders (SRBD) including obstructive sleep apnea (OSA) [4].
• During waking ten of 16 SRBD subjects and only one subject without SRBDs exhibited either an elevated nasopharyngeal airway resistance (n = 4) or a reduced ventilatory response to hypercapnia (n = 4) and/or hypoxia (n = 3) [5].

Psychiatry related information on SRBD1

• Having both insomnia symptoms and SRBD was associated with significantly lower daytime functioning and longer psychomotor reaction times compared with having neither condition [6].
• Recent studies show that SRBD are extremely common in EH but that the vast majority of patients with these sleep disorders are being missed by physicians who are treating the accompanying hypertension, even when the patients already have blatant symptoms of OSA [7].
• In comparison with normal values, scores for all HRQL dimensions were decreased in SRBD patients, with a greater impact on subscores for "vitality", "physical role", "social functioning", "mental health" and "role emotional" dimensions [8].
• In particular, the consequences of SRBD on cardiac arrhythmias, arterial hypertension and hypersomnolence are discussed, considering epidemiological, clinical, diagnostic and therapeutic aspects [9].
• Over the last two decades the diagnostic tools used in sleep medicine have developed enormously, making it possible to study the interaction of sleep-related breathing disorders (SRBD) with cardiovascular function and the autonomic nervous system, as well as the effects of SRBD on a variety of physiological processes during wakefulness [9].

High impact information on SRBD1

• The exact influence of sleep-related breathing disorder (SRBD) on blood pressure control remains unknown [1].
• These cross-sectional clinical data suggest a relationship between SRBD severity and systolic blood pressure, diastolic blood pressure, and heart rate after control for confounders such as body mass index (BMI), age, alcohol/nicotine consumption, cholesterol level, and daytime PO(2) and PCO(2) [1].
• Arrhythmia analysis and screening for SRBD can be performed in a single-step approch [10].
• Sleep-related breathing disorders (SRBD) like Cheyne-Stokes Respiration (CSR) or obstructive sleep apnea (OSAS) are often observed in patients with severe HF resulting in fragmentation of sleep, excessive daytime sleepiness and an increased mortality [11].
• Snoring is an important sign of sleep-related breathing disorders (SRBD), of the upper airway resistance syndrome (UARS), and of the OSAS [12].

Biological context of SRBD1

• The issue of ambulatory diagnosis of SRBD has gained importance in Germany because beginning in spring 1992 physicians will be reimbursed if they continuously record respiratory signals, heart rate, oxygen saturation and movement in their patients and if they qualify by attending a one-week training course [13].
• Home monitoring of snoring is very useful for epidemiology and is mandatory, together with heart rate and arterial oxygen saturation (Sa,O2), to screen SRBD [12].

Anatomical context of SRBD1

• Thus, coronary artery patients who were complicated with SRBD showed poor cardiac function and had a high incidence of cardiac events [14].

Associations of SRBD1 with chemical compounds

• AMADS: Clonazepam, Opioid, Apomorphine infusion; RBD: Clonazepam and dopaminergic agonists; SRBD: CPAP, UPPP, nasal interventions, losing weight; SRH: Clozapine, Risperidone; SRPD: Nortriptyline, Clozapine, Olanzepine; SA-adjustment; EDS-arousing drugs [15].

Analytical, diagnostic and therapeutic context of SRBD1

• METHODS: Men (n = 788) and women (n = 620) randomly selected from a working population were evaluated for SRBD by in-laboratory polysomnography and for depression by the Zung depression scale [16].
• Body mass index (calculated as weight in kilograms divided by height in meters squared) of 30 or higher, neck circumference greater than 15.5 inches, and a history of "loud snoring" or "stops breathing, chokes, or struggles for breath" were independently predictive of SRBD in participants with insomnia symptoms [6].
• This population-based epidemiological study assesses SRBD as a longitudinal predictor of depression [16].
• OBJECTIVES: To evaluate, prospectively, the diagnostic value of nocturnal home oximetry in identifying SRBD in CHF patients and in distinguishing central events from obstructive events [17].
• The EEG slowing was independent of hypoxaemia, severity of SRBD, or degree of sleep disruption [18].

References